Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
05 May 2025
| Name: | SIENNA CANCER DIAGNOSTICS LIMITED (SDX) |
| ISIN: | AU000000SDX1 |
| Date of Listing: | 03 August 2017 |
| Date of Delisting: | 29 July 2020 |
Stock Exchange Status:
This entity was delisted from the Australian Securities Exchange on 29 July 2020.Legal Status:
To our knowledge this entity was the subject of a takeover or merger such that your securities were acquired for consideration in the form of cash or scrip. We have not therefore verified the current legal status of this entity. If you have questions about your shareholding, as we say elsewhere, they may be taken up here: https://www.delisted.com.au/TraceLostSharesLostMoney/index/.Capital Gains Tax (CGT) Status:
To our knowledge this entity was the subject of a takeover or merger such that your securities were acquired for consideration in the form of cash or scrip. You will need to seek independent tax advice in relation to Capital Gains Tax or other tax matters but any other enquiries relating to your shareholding in the company should be followed up via our online form here: https://www.delisted.com.au/TraceLostSharesLostMoney/index/.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
REGISTRY:
Link Market Services Melbourne
Tower 4, 727 Collins Street Docklands VIC 3008
Tel : +61 3 9615 9800 or 61 1300 554 474
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail
delisted from the close of trading on Wednesday, 29 July 2020, pursuant to Listing rule 17.11. | 29/07/2020 |
we understand BARD1 Life Sciences was successful with an offer of 13 new ordinary shares in BARD1 for every 5 Sienna shares | 29/07/2020 |
The scheme of arrangement between Sienna and its shareholders in relation to the acquisition of all shares in Sienna by BARD1 Life Sciences was implemented today. This follows approval by shareholders on 15 July 2020 and approval of the scheme by the Federal Court of Australia on 20 July 2020. Eligible former Sienna shareholders have been issued 13 new ordinary shares in BARD1 for every 5 Sienna shares they held as at the Scheme record date being 23 July 2020. | 28/07/2020 |
The securities of Sienna Cancer Diagnostics Limited will be suspended from quotation at the close of trading today, Monday, 20 July 2020, in accordance with Listing Rule 17.2, following lodgement of the Federal Court of Australia orders with the Australian Securities and Investments Commission approving the scheme of arrangement by which BARD1 Life Sciences Limited will acquire all of the issued shares in SDX. | 20/07/2020 |
The suspension of trading in the securities of Sienna Cancer Diagnostics Limited will be lifted immediately, following the release by SDX of an announcement regarding a capital raising. | 29/11/2019 |
Sienna to raise up to approximately $4.2 million, before costs, via a share placement and rights issue at 3.5 cents per share. Issue price of 3.5 cents per share represents a 20% discount to the 30-day Volume Weighted Average Price (VWAP) of Sienna's shares traded on the ASX as at 25 November 2019, and a 13% premium to the last traded price of Sienna shares (being 3.1 cents on 25 November 2019). Funds will be used for further development of SIEN NETTM, co-development expenditures for the collaborative agreements with Minomic International Ltd and VivaZome Therapeutics Pty Ltd, and continued evaluation of potential technologies for acquisition or in-license. | 29/11/2019 |
The securities of Sienna Cancer Diagnostics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of SDX, pending the release of an announcement regarding a capital raising. | 28/11/2019 |
listed entity carried for record purposes only | 03/08/2017 |
delisted from the close of trading on Wednesday, 29 July 2020, pursuant to Listing rule 17.11. | 29/07/2020 |
we understand BARD1 Life Sciences was successful with an offer of 13 new ordinary shares in BARD1 for every 5 Sienna shares | 29/07/2020 |
The scheme of arrangement between Sienna and its shareholders in relation to the acquisition of all shares in Sienna by BARD1 Life Sciences was implemented today. This follows approval by shareholders on 15 July 2020 and approval of the scheme by the Federal Court of Australia on 20 July 2020. Eligible former Sienna shareholders have been issued 13 new ordinary shares in BARD1 for every 5 Sienna shares they held as at the Scheme record date being 23 July 2020. | 28/07/2020 |
The securities of Sienna Cancer Diagnostics Limited will be suspended from quotation at the close of trading today, Monday, 20 July 2020, in accordance with Listing Rule 17.2, following lodgement of the Federal Court of Australia orders with the Australian Securities and Investments Commission approving the scheme of arrangement by which BARD1 Life Sciences Limited will acquire all of the issued shares in SDX. | 20/07/2020 |
The suspension of trading in the securities of Sienna Cancer Diagnostics Limited will be lifted immediately, following the release by SDX of an announcement regarding a capital raising. | 29/11/2019 |
Sienna to raise up to approximately $4.2 million, before costs, via a share placement and rights issue at 3.5 cents per share. Issue price of 3.5 cents per share represents a 20% discount to the 30-day Volume Weighted Average Price (VWAP) of Sienna's shares traded on the ASX as at 25 November 2019, and a 13% premium to the last traded price of Sienna shares (being 3.1 cents on 25 November 2019). Funds will be used for further development of SIEN NETTM, co-development expenditures for the collaborative agreements with Minomic International Ltd and VivaZome Therapeutics Pty Ltd, and continued evaluation of potential technologies for acquisition or in-license. | 29/11/2019 |
The securities of Sienna Cancer Diagnostics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of SDX, pending the release of an announcement regarding a capital raising. | 28/11/2019 |
listed entity carried for record purposes only | 03/08/2017 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NATURE | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|---|
| 13/09/2017 | John Chiplin | 75,000 | $0.140 | $10,500 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Helen Fisher | Independent Director | 28/03/2018 |
| Philip Powell | Non Exec Director | 28/07/2020 |
| Geoffrey Cumming | Non Exec Director | 27/01/2006 |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Carl Stubbings | Executive Director, CEO | 31/12/2011 | 28/07/2020 |
| Tony Di Pietro | Executive Director, CFO, Company Secretary | 01/11/2014 | 28/07/2020 |
| David Earp | Non Exec Director | 01/12/2012 | 14/11/2019 |
| Matthew Hoskin | CEO | 04/02/2014 | 16/10/2019 |
| John Chiplin | Non Exec Director | 22/01/2016 | 30/09/2018 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
